ABIRATERONE TEVA 250 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

ABIRATERONE ACETATE

متاح من:

TEVA ISRAEL LTD

ATC رمز:

L02BX03

الشكل الصيدلاني:

TABLETS

تركيب:

ABIRATERONE ACETATE 250 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

TEVA ISRAEL LTD, ISRAEL

المجال العلاجي:

ABIRATERONE

الخصائص العلاجية:

Abiraterone Acetate is a CYP17 inhibitor indicated:- in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.- for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

تاريخ الترخيص:

2022-05-31

نشرة المعلومات

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s prescription only
ABIRATERONE TEVA 250 MG
TABLETS
ABIRATERONE TEVA 500 MG
TABLETS
EACH TABLET OF ABIRATERONE TEVA 250 MG CONTAINS:
Abiraterone acetate 250 mg
EACH TABLET OF ABIRATERONE TEVA 500 MG CONTAINS:
Abiraterone acetate 500 mg
For information regarding inactive ingredients and allergens, see
section 2 “Important information about some of the ingredients
of the medicine” and section 6 “Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE.
This leaflet contains concise information about the medicine.
If you have additional questions, refer to the doctor or the
pharmacist.
This medicine has been prescribed for treatment of your
illness. Do not pass it on to others. It may harm them even if it
seems to you that their medical condition is similar.
1. WHAT IS THE MEDICINE INTENDED FOR?
Abiraterone Teva is a prescription medicine containing an
active ingredient called abiraterone acetate.
Abiraterone Teva inhibits the enzyme CYP17. It is given along
with prednisone for the treatment of castration-resistant metastatic
prostate cancer.
It is also intended for the treatment of adult males with newly
diagnosed high risk metastatic hormone-sensitive prostate
cancer (mHSPC) in combination with androgen deprivation
therapy (ADT).
THERAPEUTIC CLASS:
Selective inhibitor of the CYP17 enzyme.
2. BEFORE USING THE MEDICINE
Do not use this medicine:
•
If you are sensitive (allergic) to abiraterone acetate or to
any of the additional ingredients the medicine contains.
For
the
list
of
additional
ingredients
see
section
6
“Additional Information”.
•
If you are a woman and especially a pregnant woman.
Abiraterone Teva is intended for use in males only.
•
If you have severe liver damage.
•
In
combination
with
Ra-223
(which
is
used
to
treat
prostate cancer).
Do not take the medicine if any of the above applies to you. If
you are unsure, consult the d